The American government is, apparently, the stocks of Remdesivir for the next three months bought. The British newspaper “The Guardian” reported. Just a few days ago, the European medicines Agency EMA had recommended approval for the agent with the trade name Veklury, subject to conditions in Europe.
An international study with over 1000 participants has shown at the end of April, that Remdesivir at Covid-19-patients can shorten the time to recovery in an average of four days – from 15 to 11 days. The mortality has not decreased in the study slightly, which was statistically significant.
“We want to be, as far as it goes, to ensure that every American Patient who needed Remdesivir, gets it,” said the American Minister of health, Alex Azar, the British daily newspaper. The American government is bought, therefore, over 500,000 doses. This is equivalent to the entire production of the American Biotech company Gilead Sciences for July, and that about 90 percent of the production for August and September.
The Federal Ministry of health is expected “this week,” the approval of the drug for the treatment of Covid-19-patients in the EU. “With the approval the obligation is connected also to a reasonable extent to provide. We expect that Gilead will follow this undertaking,” said a spokesman for the Ministry in Berlin on Wednesday. “The Federal government has secured an early Remdesivir for the treatment of Corona patient”, added the spokesman. “At the moment there are still enough reserves.”
treatment costs
On Monday, Gilead Sciences had set the price for the active ingredient Remdesivir for the American market. A five-day treatment with Remdesivir will cost at the time of order by the government of 2340 dollars (about 2000 Euro) per Patient, wrote Gilead CEO Daniel O’day on Monday in an open letter. This net amount is also planned for Germany, said the spokesman of Gilead Sciences in Germany, Martin flörke Meier, on Tuesday. Currently Remdesivir be thought of as a pure hospital product. The System does not provide for different prices for both statutory and private funds.
